Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.

Authors

Katherine Mackey¹, Devan Kansagara¹, Kathryn Vela¹

Affiliation

¹ VA Portland Health Care System, Portland, Oregon (K.M., D.K., K.V.).

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Betacoronavirus
COVID-19
Coronavirus Infections* / epidemiology
Humans
Pandemics*
Pneumonia, Viral* / epidemiology
SARS-CoV-2
Severe Acute Respiratory Syndrome*

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins